Notes from the lab and the studio — clinical trial updates, the neuroscience behind Meliora, cognitive-training science, product design and company news.
Browse by topic
Our latest cohort showed clinically meaningful reductions in depressive symptoms, with effect sizes comparable to psychotherapy but reached faster. Investigational — not yet cleared by regulators.
Why hypoactivity in the fronto-parietal control network is a tractable target — and how adaptive gameplay is designed to recruit it session after session.
A look at how our game designers balance therapeutic load with story, so adherence comes from immersion rather than streaks and badges.
Difficulty that adapts to in-session performance keeps training in the optimal zone — the difference between a treatment and a distraction.
From PHQ-9 to objective cognitive endpoints — how we measure whether Meliora is working, and why we report the limits as plainly as the wins.
Funding from Techstars, Innovestor, Newfund and the Aalto Start-Up Center extends our clinical roadmap and grows the team in Espoo.
Baseline profiling, real-time difficulty and pacing — the adaptive loop that makes the same product fit very different people.
Recruitment, controls and engagement tracking when your intervention is software — lessons from standing up our pivotal study.
Selected into the 2023 Techstars Accelerator, joining a global program supporting promising early-stage health and technology companies.
How ten years of Aalto University neuroscience on cognition and depression became the foundation for a precision digital therapeutic.
Stay in the loop
Occasional updates on trials, neuroscience and Meliora. No spam — unsubscribe any time.
For trial collaborations, data requests or press enquiries about our science, reach out — we're glad to talk.
